Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Journal of Comparative Effectiveness Research|August 24, 2021
Potential policy reforms to strengthen the accelerated approval pathwayAnna Kaltenboeck, Amanda Mehlman, Steven D Pearson
JAMA Internal Medicine|May 8, 2013
Cost consideration in the clinical guidance documents of physician specialty societies in the United StatesJennifer A T Schwartz, Steven D Pearson
Health Affairs (Project Hope)|April 8, 2011
Measuring the performance of individual physicians by collecting data from multiple health plans: the results of a two-state testAparna Higgins, Timothy Zeddies, Steven D Pearson
Journal of Comparative Effectiveness Research|August 10, 2022
The next generation of rare disease drug policy: ensuring both innovation and affordabilityCaroline Pearson, Lindsey Schapiro, Steven D Pearson
Health Affairs (Project Hope)|December 8, 2011
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatmentScott D Ramsey, David Veenstra, Sean R Tunis, et al.
Health Affairs Scholar|March 24, 2025
Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturersSean R Tunis, Jason Shafrin, Kyi-Sin Than, et al.
Journal of General Internal Medicine|November 11, 2010
The diagnostic performance of multi-slice coronary computed tomographic angiography: a systematic reviewDaniel A Ollendorf, Michelle Kuba, Steven D Pearson
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?Logan Trenaman, Steven D Pearson, Jeffrey S Hoch
Plos One|March 6, 2012
How well do randomized trials inform decision making: systematic review using comparative effectiveness research measures on acupuncture for back painClaudia M Witt, Eric Manheimer, Richard Hammerschlag, et al.
Contemporary Clinical Trials|September 4, 2013
Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payersSeema S Sonnad, C Daniel Mullins, Danielle Whicher, et al.
Pageof 16